OSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win

Summary: A new study shows that combining a special vaccine with the drug Keytruda can help women with ovarian cancer. The vaccine is designed to turn "cold" tumors into "hot" ones, which helps the body's immune system see and attack the cancer. In the trial, women using this new combo lived longer without their cancer growing—4.1 months compared to 2.8 months for those on standard care. This could bring new hope and extra time for patients fighting the disease.

Source: rssapp-fiercebiotech-com URL: fiercebiotech.com/biotech/ose-turns-heat-ovarian-cancer-phase-2-keytruda-supported-win (opens in new tab)